FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.
What happened
FDA inspected the clinical site from October 7 to October 18, 2024, as part of its Bioresearch Monitoring Program. FDA found that the investigator did not follow the investigational plan when a subject received about 1060 mcg of an investigational drug instead of the intended 10.674 mcg, about 100 times the protocol-required dose, after dilution procedures were not followed. The subject was hospitalized with serious adverse events, including cardiac arrest, and died.
What FDA found
The investigator failed to ensure the investigation was conducted according to the investigational plan; a subject received about 100 times the protocol-required dose after dilution procedures were not followed.
21 CFR 312.60
What FDA wants
Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations and provide sufficient details on how the investigator will oversee study procedures. Failure to address the matter adequately may lead to regulatory action.
Who should pay attention
- clinical investigators running drug trials
- sponsors and IRBs overseeing investigational drug studies
- oncology research pharmacies and compounding staff
This is a summary. Read the original letter on fda.gov.